Phasenprophylaxe bipolarer Erkrankungen

Lernziele

Dieser Artikel soll aktuelle Empfehlungen zur Phasenprophylaxe bipolarer Erkrankungen vermitteln. Zudem werden mögliche Überlegungen bei der Indikationsstellung für eine Langzeittherapie wie auch bei der Auswahl einer passenden pharmakologischen Prophylaxe dargestellt. Darüber hinaus werden Zielsetzungen einer Phasenprophylaxe sowie nicht-pharmakologische Aspekte einer Langzeittherapie erläutert.

• Literatur

• 1 Goodwin GM, Martinez-Aran A, Glahn DC et al. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008; 18: 787-793
• 2 Association AP. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159: 1-50
• 3 Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6: 504-518
• 4 Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-739
• 5 National Collaborating Centre for Mental Health (UK). Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE clinical guideline 38. Leicester (UK): British Psychological Society; 2006
• 6 DGBS e. V. und DGPPN e. V.: S3-Leitlinie zur Diagnostik und Therapie Bipolarer Störungen. Langversion 1.8. Mai 2012, letzte Anpassung Januar 2014
• 7 Saß H, Wittchen HU, Zaudig M. Diagnostisches und statistisches Manual psychischer Störungen DSM-IV. Göttingen: Hogrefe; 1996
• 8 Association AP. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association; 1994
• 9 WHO. Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V, Klinisch-diagnostische Leitlinien. 4. Aufl. Bern: Hans Huber; 2000
• 10 Tohen M, Frank E, Bowden CL et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453-473
• 11 Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004; 161: 3-18
• 12 Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146-151
• 13 Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. Journal Clin Psychiatry 2006; 67: 626-637
• 14 Keck PE, Calabrese JR, McIntyre RS et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480-1491
• 15 Krüger S. Olanzapin in der Behandlung bipolarer affektiver Erkrankungen. Psychiatr Prax 2006; 33 (Suppl. 01) S18-S26
• 16 Geddes JR, Burgess S, Hawton K et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217-222
• 17 Smith LA, Cornelius V, Warnock A et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412
• 18 Severus WE, Kleindienst N, Seemuller F et al. What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review?. Bipolar Disord 2008; 10: 231-237
• 19 Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247-256
• 20 Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281-1290
• 21 Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
• 22 Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400
• 23 Vieta E, Suppes T, Eggens I et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008; 109: 251-263
• 24 Vieta E, Berk M, Wang W et al. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord 2009; 119: 22-27
• 25 Colom F, Vieta E, Daban C et al. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006; 93: 13-17
• 26 Baldessarini RJ, Tondo L, Davis P et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord 2006; 8: 625-639
• 27 Cipriani A, Pretty H, Hawton K et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-1819
• 28 Maj M, Pirozzi R, Starace F. Previous pattern of course of the illness as a predictor of response to lithium prophylaxis in bipolar patients. J Affect Disord 1989; 17: 237-241
• 29 Faedda GL, Baldessarini RJ, Tohen M et al. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991; 148: 1237-1239
• 30 Bowden CL, Brugger AM, Swann AC et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Jama 1994; 271: 918-924
• 31 Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium?. J Affect Disord 1986; 10: 115-125
• 32 Maj M. Effectiveness of lithium prophylaxis in schizoaffective psychoses: application of a polydiagnostic approach. Acta Psychiatr Scand 1984; 70: 228-234
• 33 Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 1981; 5: 507-510
• 34 Abou-Saleh MT. Platelet MAO, personality and response to lithium prophylaxis. J Affect Disord 1983; 5: 55-65
• 35 Gaviria M, Flaherty J, Val E. A comparison of bipolar patients with and without a borderline personality disorder. Psychiatr J Univ Ott 1982; 7: 190-195
• 36 Kutcher SP, Marton P, Korenblum M. Adolescent bipolar illness and personality disorder. J Am Acad Child Adolesc Psychiatry 1990; 29: 355-358
• 37 Post RM, Leverich GS, Kupka RW et al. Early-onset bipolar disorder and treatment delay are risk factors for poor outcome in adulthood. J Clin Psychiatry 2010; 71: 864-872
• 38 Franchini L, Zanardi R, Smeraldi E et al. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci 1999; 249: 227-230
• 39 Garcia-Lopez A, Ezquiaga E, Nieves P et al. Clinical predictors of long-term outcome of lithium prophylaxis in bipolar disorder. Actas Esp Psiquiatr 2001; 29: 327-332
• 40 Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255
• 41 Goodwin GM. Consensus Group of the British Association for P. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388
• 42 Licht RW, Vestergaard P, Kessing LV et al. Psychopharmacological treatment with lithium and antiepileptic drugs: suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 419: 1-22
• 43 Sachs GS, Printz DJ, Kahn DA et al. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000. Postgrad Med 2000; Spec No: 1-104
• 44 Nolen WA, Kupka RW, Schulte PFJ et al. Richtlijn bipolaire stoornissen. Utrecht 2008
• 45 Merikangas KR, Akiskal HS, Angst J et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543-552
• 46 Rihmer Z, Pestality P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am 1999; 22: 667-673
• 47 Baastrup PC. The Use of Lithium in Manic-Depressive Psychosis. Compr Psychiatry 1964; 10: 396-408
• 48 Hartigan GP. The Use of Lithium Salts in Affective Disorders. Br J Psychiatry 1963; 109: 810-814
• 49 Baastrup PC, Poulsen JC, Schou M et al. Prophylactic lithium: double blind discontinuation in manic-depressive and recurrent-depressive disorders. Lancet 1970; 2: 326-330
• 50 Coppen A, Noguera R, Bailey J et al. Prophylactic lithium in affective disorders. Controlled trial. Lancet 1971; 2: 275-279
• 51 Cundall RL, Brooks PW, Murray LG. A controlled evaluation of lithium prophylaxis in affective disorders. Psychol Med 1972; 2: 308-311
• 52 Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: A double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976; 33: 117-120
• 53 Fieve RR, Dunner DL, Kumbaraci T et al. Lithium carbonate prophylaxis of depression in three subtypes in primary affective disorder. Pharmakopsychiatr Neuropsychopharmakol 1976; 9: 100-107
• 54 Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Pres; 2007
• 55 Maj M. The impact of lithium prophylaxis on the course of bipolar disorder: a review of the research evidence. Bipolar Disord 2000; 2: 93-101
• 56 Licht RW. Lithium: still a major option in the management of bipolar disorder. CNS Neurosci Ther 2012; 18: 219-226
• 57 Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481-489
• 58 Bowden CL, Lecrubier Y, Bauer M et al. Maintenance therapies for classic and other forms of bipolar disorder. J Affect Disord 2000; 59 (Suppl. 01) S57-S67
• 59 Goodwin GM, Geddes JR. Latest maintenance data on lithium in bipolar disorder. Eur Neuropsychopharmacol 2003; 13 (Suppl. 02) S51-S55
• 60 Kane JM, Quitkin FM, Rifkin A et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065-1069
• 61 Geddes JR. BALANCE investigators and collaborators et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-395
• 62 Mander AJ, Loudon JB. Rapid recurrence of mania following abrupt discontinuation of lithium. Lancet 1988; 2: 15-17
• 63 Burrow GN, Burke WR, Himmelhoch JM et al. Effect of lithium on thyroid function. J Clin Endocrinol Metab 1971; 32: 647-652
• 64 Schiemann U, Hengst K. Thyroid echogenicity in manic-depressive patients receiving lithium therapy. J Affect Disord 2002; 70: 85-90
• 65 Mak TW, Shek CC, Chow CC et al. Effects of lithium therapy on bone mineral metabolism: a two-year prospective longitudinal study. J Clin Endocrinol Metab 1998; 83: 3857-3859
• 66 Berger M, Riedel M, Tomova N et al. Do current screening recommendations allow for early detection of lithium-induced hyperparathyroidism in patients with bipolar disorder?. Int J Bipolar Disord 2013; 1: 7
• 67 Yamaki M, Kusano E, Tetsuka T et al. Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats. Am J Physiol 1991; 261: F505-F511
• 68 Tredget J, Kirov A, Kirov G. Effects of chronic lithium treatment on renal function. J Affect Disord 2010; 126: 436-440
• 69 Bendz H, Schon S, Attman PO et al. Renal failure occurs in chronic lithium treatment but is uncommon. Kidney Int 2010; 77: 219-224
• 70 McKnight RF, Adida M, Budge K et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012; 379: 721-728
• 71 Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand Suppl 2005; 13-20
• 72 Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 2003; 28: 1374-1382
• 73 Tohen M, Ketter TA, Zarate CA et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263-1271
• 74 Rasgon NL, Altshuler LL, Fairbanks L et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246-259
• 75 European Medicines Agency. Questions and answers on the review of medicines containing valproate for use in bipolar disorder. EM Agency; 2010
• 76 Greil W, Ludwig-Mayerhofer W, Erazo N et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders--a randomised study. J Affect Disord 1997; 43: 151-161
• 77 Hartong EG, Moleman P, Hoogduin CA et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144-151
• 78 Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 (Suppl. 01) S2-S10
• 79 Greil W, Kleindienst N. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol 1999; 14: 283-285
• 80 Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14: 277-281
• 81 Licht RW, Nielsen JN, Gram LF et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010; 12: 483-493
• 82 Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009; 8: 16
• 83 Marcus R, Khan A, Rollin L et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133-144
• 84 Weisler RH, Nolen WA, Neijber A et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011; 72: 1452-1464
• 85 Young AH, McElroy SL, Olausson B et al. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry 2014; 15: 96-112
• 86 Suppes T, Vieta E, Liu S et al. Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry 2009; 166: 476-488
• 87 Quiroz JA, Yatham LN, Palumbo JM et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156-162
• 88 Bowden CL, Vieta E, Ice KS et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130-137
• 89 Keck PE, Versiani M, Potkin S et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741-748
• 90 Seemuller F, Forsthoff A, Dittmann S et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert opinion on drug safety 2005; 4: 849-868
• 91 Vieta E, Grunze H. Bipolar disorder – a focus on depression. N Engl J Med 2011; 364: 1581 Author Reply 1582
• 92 Frye MA. Clinical practice. Bipolar disorder--a focus on depression. N Engl J Med 2011; 364: 51-59
• 93 Frye MA, Helleman G, McElroy SL et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166: 164-172
• 94 Leverich GS, Altshuler LL, Frye MA et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239
• 95 Nolen WA, Kupka RW, Hellemann G et al. Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study. Acta Psychiatr Scand 2007; 115: 360-365
• 96 Altshuler L, Kiriakos L, Calcagno J et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612-616
• 97 Amsterdam JD, Luo L, Shults J. Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. Br J Psychiatry 2013; 202: 301-306
• 98 Grande I, de Arce R, Jimenez-Arriero MA et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int J Neuropsychopharmacol 2013; 16: 513-523
• 99 Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007; 10: 123-129
• 100 Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407
• 101 Seemuller F, Berger M, Musil R et al. The challenge of treating bipolar outpatients. Fortschritte der Neurologie-Psychiatrie 2013; 81 (Suppl. 01) S35-S39
• 102 Quill TE, Brody H. Physician recommendations and patient autonomy: finding a balance between physician power and patient choice. Ann Intern Med 1996; 125: 763-769
• 103 Zeber JE, Copeland LA, Good CB et al. Therapeutic alliance perceptions and medication adherence in patients with bipolar disorder. J Affect Disord 2008; 107: 53-62
• 104 Malhi GS, Ivanovski B, Hadzi-Pavlovic D et al. Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007; 9: 114-125
• 105 Ayuso-Mateos JL. Global Burden of Bipolar Disorder in the Year 2000. Geneva: World Health Organization; Stand: 21.6.2006
• 106 Murray CL, Lopez AD. The Global Burden of Disease. Cambridge: Harvard University Press; 1996